A New Approach to Hearing Loss
Hearing plays an important role in everyday life, from conversations with loved ones to enjoying music. But for some individuals, hearing can suddenly decline without an obvious explanation.
This condition, known as sudden sensorineural hearing loss, affects the inner ear or the pathways responsible for transmitting sound signals to the brain. Although treatments such as corticosteroids can help some patients, others experience little improvement.
A 2026 clinical study published in Stem Cell Research & Therapy explored whether particles released by umbilical cord-derived stem cells could offer a new approach for patients who had not responded adequately to conventional treatment.
How Do Stem Cell-Derived Vesicles Work?
The treatment involved small extracellular vesicles (sEVs) derived from human umbilical cord mesenchymal stem cells.
These microscopic particles act as communication packages, carrying proteins and other biological molecules that influence cellular activity. Researchers are particularly interested in their potential to regulate inflammation, reduce cellular stress, and support tissue-protective processes.
Unlike traditional stem cell therapies, this approach does not involve transplanting living cells. Instead, it explores whether the biological signals released by stem cells could provide therapeutic benefits.
Inside the Clinical Trial
This Phase 1 clinical trial was conducted in China and involved 13 patients with persistent sudden hearing loss who had previously received corticosteroid treatment without meaningful recovery. Twelve participants completed the eight-week follow-up.
The treatment involved:
- Five consecutive days of injections containing stem cell-derived vesicles into the middle ear.
- Four dosage levels to evaluate safety across different concentrations.
- Eight weeks of follow-up to monitor side effects and changes in hearing.
The primary objective was to evaluate safety and tolerability, while hearing tests provided preliminary information about potential effectiveness.
Encouraging Signs of Hearing Improvement
Although safety was the main focus, researchers observed some interesting changes in participants’ hearing. Five of the 12 participants experienced hearing threshold improvements of at least 15 decibels by the end of the study, indicating an improved ability to detect sounds during hearing tests.
Interestingly, these improvements occurred among participants receiving the two lower treatment concentrations rather than the higher doses.
Researchers also noticed that participants who responded had experienced hearing loss for 22 days or less before treatment. This suggests that treatment timing may be worth investigating in future studies.
However, because the trial did not include a control group, researchers could not determine whether these improvements resulted directly from the therapy or other factors, including natural recovery.
What Did the Study Reveal About Safety?
The safety findings were encouraging, with no serious adverse events or dose-limiting toxicities reported during the eight-week follow-up. Some participants experienced temporary side effects, including mild ear pain, fullness in the ear, and brief dizziness. These symptoms resolved without additional treatment.
Researchers also found no meaningful treatment-related abnormalities in routine laboratory testing.
Why This Research Matters
One of the most interesting aspects of this study is its use of cell-free regenerative medicine. Instead of transplanting stem cells, researchers are investigating whether extracellular vesicles can deliver beneficial cellular signals to areas affected by injury or disease.
For hearing loss, this approach could potentially help protect vulnerable inner ear cells and influence biological processes involved in auditory function.
However, the study did not demonstrate regeneration of damaged hearing cells or establish that the treatment can permanently restore hearing.
Looking Toward the Future
While the findings offer an encouraging early look at this approach, the study included a small number of participants and only eight weeks of follow-up. Larger randomized controlled trials will be needed to confirm effectiveness, determine appropriate dosing, and evaluate long-term safety.
Nevertheless, this research highlights an exciting direction in regenerative medicine, showing how scientists are exploring the therapeutic potential of stem cell-derived particles for conditions that remain difficult to treat.
Source
Shu F, Wu Y, Zhang Y, et al. Intratympanic injection of human umbilical cord mesenchymal stem cell derived small extracellular vesicles for refractory sudden sensorineural hearing loss: a Phase 1 trial. Stem Cell Research & Therapy. 2026;17:322. DOI: 10.1186/s13287-026-05136-9. Available from: https://link.springer.com/article/10.1186/s13287-026-05136-9
Related Treatment Pages